RU58841 and High-Strength Minoxidil: The Regulatory Facts

RU58841 status

RU58841 is an experimental topical antiandrogen originally investigated decades ago and never brought to market. It has no FDA approval in any country, and there are no published controlled human trials establishing its efficacy or safety. Development was discontinued; the compound survives only as a gray-market research chemical. Long-term human safety is entirely unstudied.

Minoxidil: what's actually approved

Topical minoxidil is FDA-approved over the counter at 2% and 5% concentrations for pattern hair loss, and it's one of only two treatments with that approval. Higher concentrations — 10% and above — are not FDA-approved formulations. They're produced by compounding pharmacies or sold online. Published dermatology literature indicates that increasing concentration above 5% yields limited additional benefit for many users while raising the incidence of side effects including scalp irritation, unwanted facial hair growth, and systemic absorption effects such as fluid retention and increased heart rate.

Why the distinction matters

Approved 5% minoxidil and unapproved 10% compounded formulations are legally and clinically different products. Only the former has been reviewed for safety and efficacy at that strength.

The evidence gap

For hair loss specifically, the treatments with actual regulatory approval and controlled trial data are topical minoxidil and finasteride. Everything else in this space — including RU58841 — is operating without that evidence base. A dermatologist is the appropriate person to discuss options with.